1. Scrip

Selectus Pharmaceuticals

 
• By Mary Stuart

Drug Delivery; Site-Specific. Selectus chemically modifies small molecule organic drugs so that they degrade quickly once they enter into the blood stream, avoiding unwanted systemic effects. Initially working with beta blocker esprolol.

Many widely-used drugs intended for a particular site of action wreak havoc on the rest of the body, causing unintended side effects which are uncomfortable for users or even prevent large percentages of patients from being able to take drugs. Beta blockers intended for angina, for example, are targeted to act on the heart, but as they circulate through other organs they can cause side effects such as chronic fatigue and impotence in 40% of the patients that take them.

Selectus Pharmaceuticalshas found a way to chemically modify small molecule organic drugs such that they degrade quickly once they enter into the blood stream, preventing them from causing unwanted side...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.